ReviewCancers2015
Next-Generation Sequencing Approaches in Cancer: Where Have They Brought Us and Where Will They Take Us?
Review in Cancers, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03557359 (A Phase II, Open Label, Single Arm Study of Nivolumab for Recurrent or Progressive IDH Mutant Gliomas With Prior Exposure to Alkylating Agents), which is not on this map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase II, Open Label, Single Arm Study of Nivolumab for Recurrent or Progressive IDH Mutant Gliomas With Prior Exposure to Alkylating Agents
Who cites it
26 citing papers in PubMed.
- The Molecular Pathology of Non-Malignant Haematological Disease.British journal of biomedical science · 2026Review
- Real-world data analysis of next-generation sequencing and corresponding clinical characteristics in thyroid tumor.Endocrine connections · 2024Article
- Genomic, transcriptomic and epigenomic sequencing data of the B-cell leukemia cell line REH.BMC research notes · 2023Article
- Method for Identifying Sequence Motifs in Pre-miRNAs for Small-Molecule Binding.ACS chemical biology · 2022Article
- Genetic and clinical profiles of 160 papillary thyroid cancers with lateral neck lymph node metastasis.Frontiers in oncology · 2022Article
- Single-Cell Sequencing: Biological Insight and Potential Clinical Implications in Pediatric Leukemia.Cancers · 2021Review
- Next-Generation Sequencing in Cancer.Journal of maxillofacial and oral surgery · 2021Review
- Integration of whole-exome and anchored PCR-based next generation sequencing significantly increases detection of actionable alterations in precision oncology.Translational oncology · 2021Article
- Article
- Genetic Variants Contributing to Early Recurrent Pregnancy Loss Etiology Identified by Sequencing Approaches.Reproductive sciences (Thousand Oaks, Calif.) · 2020Review
- Integrated analysis identifies DUSP5 as a novel prognostic indicator for thyroid follicular carcinoma.Thoracic cancer · 2020Article
- Targeted Next-Generation Sequencing Validates the Use of Diagnostic Biopsies as a Suitable Alternative to Resection Material for Mutation Screening in Colorectal Cancer.Molecular diagnosis & therapy · 2019Article
- New functionalities in the TCGAbiolinks package for the study and integration of cancer data from GDC and GTEx.PLoS computational biology · 2019Article
- Cancer biomarker discovery and translation: proteomics and beyond.Expert review of proteomics · 2019Article
- Application of next-generation sequencing technology to precision medicine in cancer: joint consensus of the Tumor Biomarker Committee of the Chinese Society of Clinical Oncology.Cancer biology & medicine · 2019Article
- Next-generation sequencing-based clinical sequencing: toward precision medicine in solid tumors.International journal of clinical oncology · 2019Review
- Osteoblast suppression in multiple myeloma bone disease.Journal of bone oncology · 2018Review
- Diagnostic value and lymph node metastasis prediction of a custom‑made panel (thyroline) in thyroid cancer.Oncology reports · 2018Article
- COSINE: non-seeding method for mapping long noisy sequences.Nucleic acids research · 2017Article
- Genome variation across cancers scales with tissue stiffness - an invasion-mutation mechanism and implications for immune cell infiltration.Current opinion in systems biology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Next-generation sequencing (NGS) technologies and data have revolutionized cancer research and are increasingly being deployed to guide clinicians in treatment decision-making. NGS technologies have allowed us to take an "omics" approach to cancer in order to reveal genomic, transcriptomic, and epigenomic landscapes of individual malignancies. Integrative multi-platform analyses are increasingly used in large-scale projects that aim to fully characterize individual tumours as well as general cancer types and subtypes. In this review, we examine how NGS technologies in particular have contributed to "omics" approaches in cancer research, allowing for large-scale integrative analyses that consider hundreds of tumour samples. These types of studies have provided us with an unprecedented wealth of information, providing the background knowledge needed to make small-scale (including "N of 1") studies informative and relevant. We also take a look at emerging opportunities provided by NGS and state-of-the-art third-generation sequencing technologies, particularly in the context of translational research. Cancer research and care are currently poised to experience significant progress catalyzed by accessible sequencing technologies that will benefit both clinical- and research-based efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.